32
Participants
Start Date
November 30, 2015
Primary Completion Date
December 31, 2016
Study Completion Date
December 31, 2016
ARC-520
Placebo
entecavir
All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
antihistamine
All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
tenofovir
All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
Universitaetsklinikum Leipzig, Leipzig
Asklepios Klinik St. Georg - Chirurgisch-Traumatologisches Zentrum, Hamburg
Medizinische Hochschule Hannover, Hanover
Klinikum der Johann Wolfgang Goethe Universitaet, Frankfurt
University Hospital of Tuebingen, Tübingen
Klinikum Der Ludwig-Maximilian-Universitaet Muenchen, München
Universitaetsklinikum Ulm, Klinik fur Innere Medizin I, Ulm
Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II, Würzburg
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Hong Kong
Eugastro Gmbh, Leipzig
Pusan National University Hospital, Busan
Gachon University Gil Medical Center, Incheon
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University College of Medicine, Seoul
Pusan National University Yangsan Hospital, Yangsan-si Gyeongnam
Lead Sponsor
Arrowhead Pharmaceuticals
INDUSTRY